AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03221556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement-Focused Care Coordination (EFCC)
Description: Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
Study NCT03221556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Education (PSE)
Description: Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
Study NCT01805011 — intervention group
Intervention type: OTHER
Intervention: minimum 4 months of breastfeeding
Study NCT03747549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Home Exercise
Description: Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
Study NCT03747549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Alone
Description: The prescribed home exercise program alone.
Study NCT01285557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)
Description: 25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Study NCT01285557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil/cisplatin (control arm)
Description: 5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Study NCT01746836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood draws.
Study NCT01746836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Starting dose: 30 mg by mouth once a day.
Study NCT01746836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Surveys completed.
Study NCT02772419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benralizumab
Description: SC administration
Study NCT02772419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration
Study NCT03079921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine
Description: Physiologic receptor blockade (α1-receptor).
Study NCT03079921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Physiologic receptor blockade (β2-receptor).
Study NCT03079921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL bag of Normal Saline Solution (NSS).
Study NCT03479814 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT-SIB plus sequential IG-RT boost
Study NCT03353688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: Deep brain stimulation
Study NCT03353688 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Boston Scientific Vercise PC IPG with directional DBS lead
Description: Deep brain stimulation
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Study NCT04386317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
Study NCT03589859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VOR Test
Description: Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
Study NCT03589859 — intervention group
Intervention type: OTHER
Intervention: Computer Game
Description: Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
Study NCT03589859 — intervention group
Intervention type: OTHER
Intervention: Nausea Scale
Description: Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
Study NCT02099864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02157532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical thrombectomy
Description: Mechanical thrombectomy using any already approved stent-retriever device
Study NCT02157532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best standard treatment
Description: Intravenous r-tPA infusion or any other medical management option
Study NCT04250857 — intervention group
Intervention type: DEVICE
Intervention: HeartStart FRX
Description: Automated External Defibrillator
Study NCT03590028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Nephrology Consult (ENC)
Description: The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
Study NCT03590028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
Study NCT01787500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01787500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01787500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01787500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01787500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: percocet
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vicodin
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dilaudid
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02110719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zofran
Study NCT00926497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided decision making
Description: Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
Study NCT06599346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.
Study NCT06599346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC Supernatant + Standard Care
Description: Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)
Study NCT03397966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human BNP(1-32)
Description: Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Study NCT03397966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (control, normal saline)
Description: Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Study NCT03300128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years - ASD
Description: The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
Study NCT03300128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circle of Parents
Description: Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings.
Study NCT06284005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRL ATP
Description: evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
Study NCT04696757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine without surgery
Study NCT03215056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: PENTHROX 3mL inhalation vapour, liquid
Study NCT03215056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT04462640 — intervention group
Intervention type: OTHER
Intervention: Management of Infant Digestive Disorders and Quality of Life
Description: The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
Study NCT00289653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm
Study NCT00270985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almonds in a calorie controlled diet
Description: Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
Study NCT00270985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nut free diet
Description: Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
Study NCT02582528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation treatment
Description: Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
Study NCT02582528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation treatment
Description: Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
Study NCT02582528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A client-centered, directive method for enhancing intrinsic motivation to change.
Study NCT01441999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Less rigid rod
Description: Titanium rod with semi rigid end
Study NCT01441999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Rod
Description: Rigid Titanium rods
Study NCT01782898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Description: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Study NCT01782898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: .9 normal saline
Description: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Study NCT04017052 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FSME-IMMUN Vaccine
Description: Booster with TBE vaccine (i.m.) FSME Immun
Study NCT04879030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Lactams
Description: The patient was randomized to use beta-lactams antibiotic
Study NCT04879030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Lactams
Description: The patient was randomized to use beta-lactams antibiotic
Study NCT04879030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone
Description: The patient was indicated to use a combination of beta-lactams and fluoroquinolones
Study NCT03502928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Control
Description: Neck Motor Control
Study NCT03502928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control
Description: Neck Motor Control
Study NCT03502928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Massage + Joint Mobilizations
Study NCT03502928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Massage + Joint Mobilizations
Study NCT03502928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling in Neck Muscles
Study NCT00878501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: oral, during 4 weeks
Study NCT00878501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, during 4 weeks
Study NCT00960622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
Study NCT00960622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivir
Description: Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
Study NCT00960622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trizivir
Description: Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
Study NCT01650532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Condition
Description: Classes lasting one hour, held 3 times per week for 8 weeks.
Study NCT01650532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Condition
Description: Classes lasting one hour, held 3 times per week for 8 weeks.
Study NCT01419236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Solution 2%
Description: Administered topically
Study NCT01419236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Administered topically
Study NCT04504734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bucillamine
Description: 100mg tablets
Study NCT04504734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg tablets
Study NCT04504734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bucillamine
Description: 200mg tablets
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participate in virtual visits with oncologist
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive 4 in-office visits with oncologist
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive 4 in-office visits with oncologist
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete electronic survey
Study NCT04054557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Use smart pill bottle
Study NCT04054557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receives time-specific reminders and messages
Study NCT01372709 — intervention group
Intervention type: DEVICE
Intervention: Ovation™ or Ovation Prime™ Abdominal Stent Graft System
Description: Single occurrence permanent implant of AAA device.
Study NCT04419025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Oral formulation: 600 mg capsules of N-acetylcysteine
Study NCT02506543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS
Description: COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
Study NCT02506543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
Study NCT02535481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidermal grafting
Description: The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
Study NCT02535481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split thickness skin grafting
Description: Split thickness skin grafting will be performed as per normal clinical practice.
Study NCT02541097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language therapy
Description: Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
Study NCT03659396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized Tai Chi
Description: individualized Tai Chi training exercise
Study NCT03659396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Entire Tai Chi
Description: the classical Yang style Tai Chi program
Study NCT03659396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: home-based program
Description: Home-based exercise
Study NCT04346745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring Program
Description: The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
Study NCT01838694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ala-Cpn10
Study NCT01838694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01630369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin human (HR1799)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous